WestPark Capital initiated coverage of Enanta (ENTA) with a Buy rating and $24 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta Pharmaceuticals Appoints Interim Financial Officers
- Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement
- Enanta files EU patent infringement suit against Pfizer
- Enanta Pharmaceuticals: Hold Rating Amid Strategic Advances and Financial Constraints
- Enanta Pharmaceuticals: Promising Outlook with Key Data Readouts and Strong Virology Pipeline